Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MiNK Therapeutics has the GF Score of 31, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes MiNK Therapeutics
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
MiNK Therapeutics (NAS:INKT) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
MiNK Therapeutics GF Score Related Terms
INKT vs BOLD, FLNA, DWTX: GF Score Comparison
For the Biotechnology subindustry, MiNK Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiNK Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where MiNK Therapeutics's GF Score falls into.
MiNK Therapeutics (INKT) has a GF Score of 31 as of Jul. 23, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on MiNK Therapeutics and its competitors. This is 48% above median its historical median of 21.00. Over the past decade, MiNK Therapeutics' GF Score has ranged from 13.00 to 40.00.
Is MiNK Therapeutics' GF Score too high?
MiNK Therapeutics' current GF Score of 31 is 48% above median its 10-year median of 21.00. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 40.00. Overall, MiNK Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' GF Score compare to BOLD and FLNA?
MiNK Therapeutics' GF Score of 31 can be compared against companies in the Biotechnology industry. Historically, MiNK Therapeutics' own GF Score has ranged from 13.00 to 40.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current GF Score is 31, which is 48% above median its own 10-year median of 21.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current GF Score of 31. The current GF Score is 31, which is 48% above median its 10-year median of 21.00. MiNK Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current GF Score is 31 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
31GF Score
Get the complete analysis for INKT
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INKT has been successfully added to your 
